Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.44 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328245 | 1.00 | HSD11B1 (0.44) | HSD11B1ACACBSIGMAR1ACHEEBP | |
| SCHEMBL19001019 | 0.81 | HSD11B1 (0.41) | HSD11B1ACACBSIGMAR1ACHEEBP | |
| SCHEMBL24124027 | 0.81 | HSD11B1 (0.50) | HSD11B1MAPK1MAPT | |
| SCHEMBL23328243 | 0.80 | HSD11B1 (0.56) | HSD11B1ACACBHRH3 | |
| SCHEMBL19000960 | 0.79 | POLB (0.45) | HSD11B1ACACBSIGMAR1HRH3NPC1 | |
| SCHEMBL19001104 | 0.79 | POLB (0.45) | HSD11B1ACACBSIGMAR1HRH3NPC1 | |
| SCHEMBL1470433 | 0.79 | HSD11B1 (0.41) | HSD11B1ACACBHRH3NPC1MAPK1 | |
| SCHEMBL19001103 | 0.79 | POLB (0.45) | HSD11B1ACACBSIGMAR1HRH3NPC1 | |
| SCHEMBL1470434 | 0.79 | HSD11B1 (0.41) | HSD11B1ACACBHRH3NPC1MAPK1 | |
| SCHEMBL19000981 | 0.79 | POLB (0.45) | HSD11B1ACACBSIGMAR1HRH3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | HSD11B1 3620/4885ACACB 3908/4885SIGMAR1 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.